5 Dec 2018 10:41
Sensyne Health welcomes UK government announcement today endorsing the potential of analysing anonymised NHS patient data in an ethical way
to improve patient care and accelerate medical research
Oxford, UK; 05 December: Sensyne Health plc (LSE: SENS), the British clinical AI technology company, welcomes the UK government's announcement today regarding the second Life Sciences Sector Deal and a consultation for a national health data policy. As a pioneer in improving patient care and generating value from anonymised patient data in an ethical way and building on the success of its work with its three NHS Foundation Trust partners, the Company has submitted a proposal to government and looks forward to continuing to help shape a national health data policy that meets the government's guiding principles to realise the full potential of NHS data whilst maintaining public trust. Sensyne is working with a set of experts (including Microsoft, EY, JP Morgan and Peel Hunt) with the requisite capabilities in computing, data analytics and systems integration to deliver such a strategy.
The NHS is the single largest integrated healthcare provider in the world covering the population of a nation from birth through to death. The UK government recognises that combining datasets both geographically and along the patient pathway of care may unlock more value than the current dispersed and locally delegated model of health data management. This could serve to increase the ability of researchers to develop actionable insights, which, in turn would help with government priorities on prevention, care and costs.
Commenting on today's announcement, Lord (Paul) Drayson, Chief Executive Officer of Sensyne Health plc, said: "Linking data-sets both geographically and longitudinally along the patient pathway offers the potential of a significant increase in the number and value of insights that can be derived to improve patient care and accelerate medical research. We believe our existing 'double bottom line' model working in partnership with the NHS is an excellent foundation for a national strategy that builds a sovereign capability in data-driven healthcare and look forward to continued discussions with government."
-ENDS-
For more information please contact:
Sensyne Health (www.sensynehealth.com) | +44 (0) 330 058 1845 | |
Lord (Paul) Drayson, Chief Executive Officer | ||
Lorimer Headley, Chief Financial Officer | ||
Julia Wilson, Director of Investor Relations | ||
Peel Hunt LLP (Nominated Adviser and Broker) | + 44 (0) 20 7418 8900 |
|
Dr Christopher Golden James Steel |
|
|
Oliver Jackson |
| |
Consilium Strategic Communications | +44 20 3709 5700 | |
Mary-Jane Elliott | ||
Sukaina Virji | ||
Melissa Gardiner | ||
sensynehealth@consilium-comms.com | ||
About Sensyne Health
Sensyne Health plc is a healthcare technology company that creates value from accelerating the discovery and development of new medicines and improving patient care through the analysis of real-world evidence from large databases of anonymised patient data in collaboration with NHS Trusts. These anonymised patient data are ethically sourced in that any analysis of anonymised patient data (and hence the Company's access to it) must be pre-approved for each programme on a case-by-case basis by the relevant NHS Trusts. This is to ensure that the purpose of the anonymisation and the proposed analysis are subject to appropriate ethical oversight and information governance, including conformance with NHS principles, UK data protection law and applicable regulatory guidance. Sensyne Health is an early signatory to the Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology'.
Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).
For more information, please visit: www.sensynehealth.com